Should you ditch Neil Woodford and buy this top-performing investment trust?

Is now the time to look elsewhere after a difficult 2017 for Neil Woodford?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Editor’s Note – 19/9/17: both the author and The Motley Fool apologise for the original version of this article, which mistakenly mentioned stocks that weren’t held by Woodford Patient Capital Trust in relation to its underperformance. Human error was at fault, and the article has now been corrected accordingly.

This year has been a particularly challenging one for Neil Woodford. He has come under sharp criticism from a range of investors for his lacklustre performance, with several of his funds delivering disappointing performance.

As such, many investors may be wondering if now is the time to look elsewhere for investment trusts to buy for the long term. Could this top-performing trust be worth buying ahead of Neil Woodford-managed funds such as the Woodford Patient Capital Trust (LSE: WPCT)?

A difficult year

Over the last year, the Woodford Patient Capital Trust has underperformed its benchmark, the UK All Companies index, by around 17.3%. In fact, it is down 3.2% on where it was this time last year. As such, it has been a relatively poor year for the trust at a time when a wide range of stocks, funds and indices have enjoyed a major Bull Run.

However, the nature of the trust suggests that over a relatively short-term timeframe it could struggle when compared to its benchmark. It focuses on early-stage and early-growth businesses which may have outstanding intellectual property, but require capital through which to develop. While they may have strong investment potential for the long term, their lack of positive correlation with market indices may mean there are years of significant under and overperformance. As such, a disappointing year for the trust may not be a fair reflection of its potential for long-term investors.

Further criticism

In the last year, the general performance of Neil Woodford-managed funds has not been as strong as many investors have come to expect. For example, he has been criticised for the performance of major holdings within some of his funds, such as AstraZeneca and Provident Financial.

Furthermore, his decision to sell GlaxoSmithKline and British American Tobacco has also caused some investors to become uncertain about his future performance outlook. Both stocks appear to offer sound forecast growth rates, and therefore some investors have been surprised that they have been sold in favour of other shares.


While the Woodford Patient Capital Trust has disappointed of late, the Troy Income & Growth Trust (LSE: TIGT) has surged 30% higher in the last three years. This means it has outperformed the wider UK Equity Income benchmark by around 7%. And with it trading at a small discount to its net asset value, it could offer good value for money for the long term.

With a dividend yield of 3.3%, the Troy Income & Growth Trust offers an inflation-beating income return. It holds a number of large, UK-listed income shares such as Shell and British American Tobacco. Therefore, it could benefit from a further weakening of the pound as Brexit uncertainty builds. It may also be able to offer defensive characteristics due to its geographical diversity on a company level.

Long-term outlook

While the Troy Income & Growth Trust appears to be worth buying, the Woodford Patient Capital Trust could also have investment potential. Neil Woodford has an excellent reputation which has been built up over a long period. He has not suddenly become a worse investor in the last year, but rather has experienced the same disappointment which ultimately inflicts all investors at some point in their investing careers.

As such, the trust and his other funds continue to have investment appeal for the long run. Indeed, with a discount of 5% to its net asset value, the recent poor performance of Woodford Patient Capital Trust could be an opportunity to buy, rather than sell.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares in Shell, British American Tobacco, AstraZeneca and GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline and Unilever. The Motley Fool UK has recommended AstraZeneca and Royal Dutch Shell B. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young black female footballer training on stadium pitch
Investing Articles

My JD Sports Fashion share price prediction for the second half of 2024

The JD Sports Fashion share price hasn't yet recovered from January’s slump. So will the retailer's stock bounce back in…

Read more »

Investing Articles

Up 47% in a week! Can the Capita share price continue to rocket?

The Capita share price has smashed the market in the last week, and Harvey Jones wonders whether it has the…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

What could the second half of 2024 have in store for the BAE Systems share price?

After a strong first six months of the year, what could be coming next for the BAE Systems share price?…

Read more »

Growth Shares

2 FTSE 100 stocks that are outperforming these MAG7 members

Jon Smith reveals some FTSE 100 stocks that offer him a viable alternative to the Magnificent 7, based on recent…

Read more »

Investing Articles

My Scottish Mortgage shares just paid me £14.88. It’s another step towards making a million

Harvey Jones has just received a measly dividend from his Scottish Mortgage shares, but he's got big, big plans for…

Read more »

Investing Articles

FTSE 100 shares: is Barclays a standout buy?

Barclays shares are among the FTSE 100's top performers and this Fool thinks they have further to go. He explains…

Read more »

Black woman using loudspeaker to be heard
Investing For Beginners

At 52-week highs, here’s what may be next for the Lloyds share price

Jon Smith notes the strong rally in the Lloyds share price in the recent past and explains why the good…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

These UK shares are stinking out my ISA. Time to sell?

Paul Summers has been reviewing some of the worst-performing UK shares in his portfolio. Has the time finally come to…

Read more »